InvestorsHub Logo
Followers 16
Posts 1063
Boards Moderated 0
Alias Born 09/01/2019

Re: urgonnatrip post# 10626

Monday, 07/20/2020 7:57:19 PM

Monday, July 20, 2020 7:57:19 PM

Post# of 16706
I would say broad Vaccine availability would be hard to achieve and implement to the populace. That Ifenprodil may be the 'treatment' for millions of already infected and those suffering lung damage and that the way it works is different than other IPF/CC/ALI treatments 'I' have seen. etc.

The knowledge from NASH morphed into the AGN concepts and has thoughtful scientific R+D along with strong leadership and a big company's visions. IMO. AGN's other 'pipeline' drugs, with their repurposed science, also are to be tested eventually too. People have posted about Kidney issues from COVID and the possible relevance of AGN's drugs.

Licensing and partnerships await any company with 'near term' Proven COVID associated successes. IMO. Maybe even 'Fast Track' status thru the USFDA, grants.

Not to mention the - CKD - IBD future is separate from COVID/IPF/CC/ALI, which I just did. LOL.
From here - AGN - we can see crystal ball possibilities, IMO...GLTA...